NGM Biopharmaceuticals, Inc. Common Stock
NGM
NGM was delisted on the 4th of April, 2024.
83 hedge funds and large institutions have $35.3M invested in NGM Biopharmaceuticals, Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 28 increasing their positions, 34 reducing their positions, and 19 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7.26% less ownership
Funds ownership: 56.97% → 49.71% (-7.3%)
12% less funds holding
Funds holding: 94 → 83 (-11)
18% less repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 34
30% less capital invested
Capital invested by funds: $50.6M → $35.3M (-$15.3M)
58% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$923K |
| 2 |
Renaissance Technologies
New York
|
+$206K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$187K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$128K |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
+$118K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$3.56M |
| 2 |
JP Morgan Chase
New York
|
-$1.22M |
| 3 |
BlackRock
New York
|
-$581K |
| 4 |
BC
Boxer Capital
San Diego,
California
|
-$535K |
| 5 |
Morgan Stanley
New York
|
-$278K |
NGM Hedge Fund Activity: Q4 2023 in Review
83 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in NGM Biopharmaceuticals, Inc. Common Stock (NGM) for Q4 2023, worth a combined $35.3M — down 30% from $50.6M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of NGM and 8 opened new positions — a net loss of 11 holders — while 34 trimmed existing stakes and 28 added.
The largest buyer was Millennium Management, adding an estimated $923K. The largest seller was EcoR1 Capital, cutting an estimated $3.56M.
- 83 institutional investors held NGM Biopharmaceuticals, Inc. Common Stock (NGM) as of Q4 2023, down from 94 in Q3 2023.
- Funds reported $35.3M of NGM Biopharmaceuticals, Inc. Common Stock stock for Q4 2023, down 30% quarter-over-quarter.
- 8 funds opened new NGM Biopharmaceuticals, Inc. Common Stock positions in Q4 2023 and 19 closed out, a net change of -11 holders.
- The largest NGM Biopharmaceuticals, Inc. Common Stock buyer in Q4 2023 was Millennium Management, an estimated $923K added.
- The largest NGM Biopharmaceuticals, Inc. Common Stock seller in Q4 2023 was EcoR1 Capital, an estimated $3.56M sold.
Based on aggregated 13F filings for Q4 2023.